Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 9, 2015, Pages 389.e1-389.e7

  Araújo, Wedson F ^a   Naves, Marcelo A ^a   Ravanini, Juliana N ^b   Schor, Nestor ^a   Teixeira, Vicente P C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiogenesis; Carcinoma; Immunohistochemistry; Pathologic; Renal cell; Renin angiotensin system

Indexed keywords

ANGIOTENSIN II; CAPTOPRIL; CD34 ANTIBODY; CD34 ANTIGEN; LOSARTAN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MICROVASCULATURE; MITOSIS; MOUSE; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; KIDNEY TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; CARCINOMA, RENAL CELL; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LOSARTAN; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84940467081     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.11.022     Document Type: Article

References (48)

1. Gross-Goupil M., François L., Quivy A., Ravaud A. Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol 2013, 7:269-277.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
3. Engelman M.F., Grande R.M., Naves M.A., de Franco M.F., Teixeira V.P.C. Integrin-linked kinase (ILK) expression correlates with tumor severity in clear cell renal carcinoma. Pathol Oncol Res 2013, 19:27-33.
4. Arsanious A., Bjarnason G.A., Yousef G.M. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer 2009, 8:20.
5. Ruys A.T., Tanis P.J., Iris N.D., van Duijvendijk P., Verhoef C., Porte R.J., et al. Surgical treatment of renal cell cancer liver metastases: a population-based study. Ann Surg Oncol 2011, 18:1932-1938.
6. Young R.C. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions?. N Engl J Med 1998, 338:1305-1306.
7. Berger A., Brandina R., Atalla M.A., Herati A.S., Kamoi K., Aron M., et al. Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. J Urol 2009, 182:2172-2176.
8. van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., Boven E. Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol 2010, 5:95-112.
9. Atkins M.B. Interleukin-2: clinical applications. Semin Oncol 2002, 29(Suppl. 7):12-17.
10. Paule B., Bastien L., Deslandes E., Cussenot O., Podgorniak M.P., Allory Y., et al. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One 2010, 5:e10715.
11. Chowdhury S., Larkin J.M., Gore M.E. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 2008, 44:2152-2161.
12. Di Lorenzo G., Autorino R., Sternberg C.N. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009, 56:959-971.
13. 2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 2009, 32:533-536.
14. Corvol P., Jeunemaitre X., Charru A., Kotelevtsev Y., Soubrier F. Role of the renin-angiotensin system in blood pressure regulation and in human hypertension: new insights from molecular genetics. Recent Prog Horm Res 1995, 50:287-308.
15. Achard J.M., Pruna A., Fernandez L.A., Hottelart C., Mazouz H., Rosa A., et al. Prevention of stroke and cancer: could angiotensin II type 1 receptor antagonists do better than angiotensin II converting enzyme inhibitors?. Am J Hypertens 1999, 12:1050-1053.
16. Lever A.F., Hole D.J., Gillis C.R., McCallum I.R., McInnes G.T., MacKinnon P.L., et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet 1998, 352:179-184.
17. Le Noble F.A., Schreurs N.H., van Straaten H.W., Slaaf D.W., Smits J.F., Rogg H., et al. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am J Physiol 1993, 264:R460-R465.
18. Le Noble F.A., Hekking J.W., Van Straaten H.W., Slaaf D.W., Struyker Boudier H.A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol 1991, 195:305-306.
19. Takeda H., Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 2001, 158:1633-1637.
20. Goldfarb D.A., Diz D.I., Tubbs R.R., Ferrario C.M., Novick A.C. Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol 1994, 151:208-213.
21. Uemura H., Ishiguro H., Nakaigawa N., Nagashima Y., Miyoshi Y., Fujinami K., et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003, 2:1139-1147.
22. Attoub S., Gaben A.M., Al-Salam S., Al Sultan M.A., John A., Nicholls M.G., et al. Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci 2008, 1138:65-72.
23. Greco A.J., Master R.G., Fokin A., Baber S.R., Kadowitz P.J. Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I. Can J Physiol Pharmacol 2006, 84:1163-1175.
24. Neo J.H., Ager E.I., Angus P.W., Zhu J., Herath C.B., Christophi C. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 2010, 10:134.
25. Neo J.H., Malcontenti-Wilson C., Muralidharan V., Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007, 22:577-584.
26. Miyajima A., Kosaka T., Asano T., Seta K., Kawai T., Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002, 62:4176-4179.
27. Ohnuma Y., Toda M., Fujita M., Hosono K., Suzuki T., Ogawa Y., et al. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomed Pharmacother 2009, 63:136-145.
28. Noguchi R., Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Yanase K., et al. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 2003, 9:6038-6045.
29. Volpert O.V., Ward W.F., Lingen M.W., Chesler L., Solt D.B., Johnson M.D., et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996, 98:671-679.
30. Kim Y.M., Hwang S., Pyun B.J., Kim T.Y., Lee S.T., Gho Y.S., et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002, 277:27872-27879.
31. Chen X., Meng Q., Zhao Y., Liu M., Li D., Yang Y., et al. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett 2013, 328:318-324.
32. Ferreira A.K., Freitas V.M., Levy D., Ruiz J.L., Bydlowski S.P., Rici R.E., et al. Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine. PLoS One 2013, 8:e57937.
33. Koh S.L., Ager E.I., Costa P.L., Malcontenti-Wilson C., Muralidharan V., Christophi C. Blockade of the renin-angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liver. Clin Exp Metastasis 2014, 31:395-405.
34. Hii S.I., Nicol D.L., Gotley D.C., Thompson L.C., Green M.K., Jonsson J.R. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998, 77:880-883.
35. 2 receptors in melanoma cells. Peptides 2010, 31:238-241.
36. Montana V., Sontheimer H. Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci 2011, 31:4858-4867.
37. Ma T., Liu L., Wang P., Xue Y. Evidence for involvement of ROCK signaling in bradykinin-induced increase in murine blood-tumor barrier permeability. J Neurooncol 2012, 106:291-301.
38. 2 of Candida albicans yeast cleaves human kininogens and releases proinflammatory peptides, Met-Lys-bradykinin and des-Arg(9)-Met-Lys-bradykinin. Biol Chem 2012, 393:829-839.
39. 1 receptor antagonist R-954 inhibits Ehrlich tumor growth in rodents. Peptides 2011, 32:1849-1854.
40. Yu H.S., Wang S.W., Chang A.C., Tai H.C., Yeh H.I., Lin Y.M., et al. Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells. Biochem Pharmacol 2014, 87:243-253.
41. Müller D.N., Luft F.C. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006, 1:221-228.
42. Hitom H., Liu G., Nishiyama A. Role of (pro)renin receptor in cardiovascular cells from the aspect of signaling. Front Biosci 2010, 2:1246-1249.
43. +-ATPase in the kidney. Hypertension 2009, 54:261-269.
44. Napoleone E., Cutrone A., Cugino D., Amore C., Di Santo A., Iacoviello L., et al. Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells. Thromb Res 2012, 129:736-742.
45. Arafat H.A., Gong Q., Chipitsyna G., Rizvi A., Saa C.T., Yeo C.J. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 2007, 204:996-1005. [discussion 1005-6].
46. Huang W., Wu Y.L., Zhong J., Jiang F.X., Tian X.L., Yu L.F. Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts. Dig Dis Sci 2008, 53:1206-1210.
47. 1R upregulation. BMC Cancer 2011, 11:274.
48. Wang L., Cai S.R., Zhang C.H., He Y.L., Zhan W.H., Wu H., et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. Chin Med J (Engl) 2008, 121:2167-2171.